Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ticagrelor + morphine + naloxone
- Development stage
- Unknown
- Lead developer
- Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of the P2Y12 receptor antagonist ticagrelor, the opioid analgesic morphine, and the opioid antagonist naloxone. This specific combination was evaluated in the NARCOTIC trial (Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor) conducted by Collegium Medicum w Bydgoszczy. The rationale for the combination is to mitigate the 'morphine effect,' where morphine-induced delay in gastric emptying and intestinal motility reduces the absorption and antiplatelet efficacy of oral P2Y12 inhibitors like ticagrelor. Naloxone, an opioid antagonist with low systemic bioavailability when given orally, is used to locally block opioid receptors in the gastrointestinal tract to restore normal motility without reversing the systemic analgesic effects of intravenous morphine.
- Other names
- ticagrelor + morphine + naloxone combinationticagrelor, morphine, and naloxone
02
Targets
P2Y12 (Purinergic P2Y12 receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on ticagrelor + morphine + naloxone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ticagrelor + morphine + naloxone.